StreetInsider.com News Articles

Dyne Therapeutics to present DMD preclinical data at NMSG meeting

Thu, 03 Sep 2026 07:30:19 -0400

Dyne Therapeutics, Inc. (Nasdaq: DYN) plans to present preclinical data for four investigational therapies for Duchenne muscular dystrophy (DMD) at the 27th Annual Neuromuscular Study Group Scientific Meeting, scheduled for September 25-27, 2026, in San Antonio, Texas.

The four development candidates — DYNE-253, DYNE-245, DYNE-244 and DYNE-255 — target DMD mutations amenable to skipping of exons 53, 45, 44 and 55, respectively. According to the company, all four are advancing into investigational new drug (IND)-enabling studies.

Data to be presented include in vitro exon skipping results for all four candidates, as well as in vivo pharmacokinetic and pharmacodynamic results for DYNE-253, including

Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting

Thu, 03 Sep 2026 07:30:00 -0400

- Data support the ongoing development of four investigational therapies for DMD amenable to skipping of exons 53, 45, 44 or 55, all of which are advancing into IND-enabling studies -

- All development candidates leverage the same FORCE™ platform as zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), which is under FDA review for exon 51 DMD -

WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it

Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting

Thu, 03 Sep 2026 07:30:00 -0400

- Data support the ongoing development of four investigational therapies for DMD amenable to skipping of exons 53, 45, 44 or 55, all of which are advancing into IND-enabling studies -

- All development candidates leverage the same FORCE™ platform as zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), which is under FDA review for exon 51 DMD -

Dyne Therapeutics to Participate in Upcoming Investor Conferences

Wed, 02 Sep 2026 07:30:00 -0400

WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences:

2026 Cantor Global Healthcare Conference, fireside chat on Friday, September 11, 2026 at 10:20 a.m. ET in New York, NY
Morgan Stanley 24^th Annual Global Healthcare Conference, fireside chat on Monday, September 14, 2026 at 9:15 a.m. ET in New York, NY
Baird 2026 Global Healthcare Conference, fireside chat

Dyne Therapeutics to Participate in Upcoming Investor Conferences

Wed, 02 Sep 2026 07:30:00 -0400

2026 Cantor Global Healthcare Conference, fireside chat on Friday, September 11, 2026 at 10:20 a.m. ET in New York, NY
Morgan Stanley 24^th Annual Global Healthcare Conference, fireside chat on Monday, September 14, 2026 at 9:15 a.m. ET in New York, NY
Baird 2026 Global Healthcare Conference, fireside chat

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 20 Aug 2026 16:05:00 -0400

WALTHAM, Mass., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 11 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 161,300 shares of Dyne’s common stock at a per share

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 20 Aug 2026 16:05:00 -0400

The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 161,300 shares of Dyne’s common stock at a per share

Form 4 Dyne Therapeutics, Inc. For: Aug 13 Filed by: Rhodes Jason P

Mon, 17 Aug 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260817/26939022.html

Form 4 Dyne Therapeutics, Inc. For: Aug 13 Filed by: Rhodes Jason P

Mon, 17 Aug 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260817/26939022.html

Form 4 Dyne Therapeutics, Inc. For: Aug 13 Filed by: Friedl-Naderer Johanna

Mon, 17 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260817/26938023.html

Form 4 Dyne Therapeutics, Inc. For: Aug 13 Filed by: Friedl-Naderer Johanna

Mon, 17 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260817/26938023.html

Form 4 Dyne Therapeutics, Inc. For: Aug 13 Filed by: Kerr Douglas

Mon, 17 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260817/26938014.html

Form 4 Dyne Therapeutics, Inc. For: Aug 13 Filed by: Kerr Douglas

Mon, 17 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260817/26938014.html

Form 4 Dyne Therapeutics, Inc. For: Aug 13 Filed by: Cox John

Mon, 17 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260817/26938002.html

Form 4 Dyne Therapeutics, Inc. For: Aug 13 Filed by: Cox John

Mon, 17 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260817/26938002.html

Form 4 Dyne Therapeutics, Inc. For: Aug 13 Filed by: Lucera Erick

Mon, 17 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260817/26937979.html

Form 4 Dyne Therapeutics, Inc. For: Aug 13 Filed by: Lucera Erick

Mon, 17 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260817/26937979.html

H.C. Wainwright Reiterates Buy Rating on Dyne Therapeutics (DYN)

Mon, 17 Aug 2026 06:42:10 -0400

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $50.00 price target on Dyne Therapeutics (NASDAQ: DYN).

The analyst commented: "Given the upcoming data readout from HARBOR, we believe a positive HARBOR outcome is encouraging for the DM1 landscape, and especially Dyne, given the upcoming ACHIEVE REC topline 1Q 2027. Given the MOA, the PoC trial data and the OLE data from Avidity, we expect HARBOR to hit its vHOT primary, the lowest hanging fruit, in our opinion. In MARINA-OLE at 4 mg/kg over one year, Avidity showed vHOT improving roughly 4 seconds versus approximately zero in a matched END-DM1

Form 144 Dyne Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.

Fri, 14 Aug 2026 17:48:00 -0400

si-local-file:///var/storage/secattach/20260814/26933036.html

Form 144 Dyne Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.

Fri, 14 Aug 2026 17:48:00 -0400

si-local-file:///var/storage/secattach/20260814/26933036.html

Form 144 Dyne Therapeutics, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.

Fri, 14 Aug 2026 17:48:00 -0400

si-local-file:///var/storage/secattach/20260814/26933037.html

Form 144 Dyne Therapeutics, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.

Fri, 14 Aug 2026 17:48:00 -0400

si-local-file:///var/storage/secattach/20260814/26933037.html

Form 144 Dyne Therapeutics, Inc. Filed by: Atlas Venture Opportunity Fund II, L.P.

Fri, 14 Aug 2026 17:47:00 -0400

si-local-file:///var/storage/secattach/20260814/26933034.html

Form 144 Dyne Therapeutics, Inc. Filed by: Atlas Venture Opportunity Fund II, L.P.

Fri, 14 Aug 2026 17:47:00 -0400

si-local-file:///var/storage/secattach/20260814/26933034.html

Form 144 Dyne Therapeutics, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.

Thu, 13 Aug 2026 17:36:00 -0400

si-local-file:///var/storage/secattach/20260813/26922931.html